All In Biotech

Drug Trial Radar · NCT05467475

A Study in Healthy Men to Test How Esomeprazole Influences the Amount of BI 1819479 in the Blood

The Effect of Multiple Doses of Esomeprazole on the Single-dose Pharmacokinetics of BI 1819479 Following Oral Administration in Healthy Male Subjects (an Open-label, Randomized, Two-way Cross-over Study)

Last checked: Nov 20, 2026Latest source record: Jan 26, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

15

Actual

Start

Oct 18, 2022

Primary completion

Jan 23, 2023

Study completion Jan 23, 2023

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Jul 20, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main objective of this trial is to investigate the effect of the proton pump inhibitor esomeprazole on the pharmacokinetics of BI 1819479 in plasma.

Conditions

  • Healthy

Interventions

  • BI 1819479Drug

    BI 1819479

  • EsomeprazoleDrug

    Esomeprazole

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)Time frame: Up to 31 days.
  2. Maximum measured concentration of the analyte in plasma (Cmax)Time frame: Up to 31 days.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Humanpharmakologisches Zentrum Biberach

    Biberach, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.